Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis

NCT01737814 is registered in ClinicalTrials.gov with Mast Therapeutics, Inc. as lead sponsor.

NCT NCT01737814
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01737814 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis
Lead sponsor
Mast Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
Not reported
Enrollment
388 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease, vaso-occlusive crisis